Cellectis S.A.

Company: Cellectis S.A.
Ticker: CLLS

Submit Your Information

If you suffered a loss on your Cellectis S.A. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. Please note that submission of this form does not by itself form an attorney-client relationship nor does filling out this form mean you have joined any lawsuit.

First Name*

Last Name*

Email*

Phone*

City

State

Country

Total # of shares

First Purchase Date

Last Purchase Date

Estimated Loss Range

Check here if you still hold any shares.

Check here if you are a current or former employee of the company.

Check here if you purchased any shares before

Additional Comments

Background

On September 14, 2026, Cellectis announced it would prioritize in vivo gene editing therapies (HEAL-101 and HEAL-201) over CAR-T cell therapies. The Company concurrently announced it plans to discontinue the development of CAR-T cell therapies lasme-cel and eti-cel. In the accompanying conference call, the Company’s Chief Medical Officer, Adrian Kilcoyne stated “Cellectis is not able finance [Eti-cel and Lasme-cel] given the time lines that we have and the limited cash resources that we have.”

On this news, shares of Cellectis declined $1.27 per share, or 40.97%, to close at $1.83 per share on September 14, 2026.

Submit Your Information